Status:
ACTIVE_NOT_RECRUITING
Evaluation of a Plasma Protein Profile as a Predictive Biomarker for Metastatic Relapse in Triple Negative Breast Cancer Patients
Lead Sponsor:
Centre Jean Perrin
Conditions:
Triple Negative Breast Cancer
Eligibility:
FEMALE
18+ years
Brief Summary
The INSTIGO study aims to assess a plasma protein profile at different stages of patient follow-up as a predictive factor of metastatic recurrence in triple negative breast cancer. It also aims to loo...
Detailed Description
The investigators propose to carry out a study that measures the concentrations of a set of plasma proteins in order to assess their ability to predict metastatic relapse of triple negative breast can...
Eligibility Criteria
Inclusion
- Female
- Age \> 18 years
- Diagnosed with primitive, non-metastatic, histologically proved, triple negative breast cancer
- Patient able to understand the French language
- Patient affiliated to social security
- Obtaining signed written consent
Exclusion
- Persons deprived of their freedom or under guardianship or incapable of giving consent
- Refusal to participate
Key Trial Info
Start Date :
November 27 2020
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
November 9 2029
Estimated Enrollment :
90 Patients enrolled
Trial Details
Trial ID
NCT04438681
Start Date
November 27 2020
End Date
November 9 2029
Last Update
December 4 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Centre Jean PERRIN
Clermont-Ferrand, France, 63011